National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Linaclotide (Constella®) is indicated for the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.

Rapid Review

Commenced Completed Outcome
28/05/2013 28/06/2013 Full Pharmacoeconomic Evaluation Not Recommended

Linaclotide (Constella®) is to be reimbursed under the Community Drugs Schemes subject to conditions.